A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.

Anthony B El-KhoueiryRobert O'DonnellThomas J SemradPhilip MackSuzette BlanchardNathan BaharyYixing JiangYun YenJohn WrightHelen ChenHeinz-Josef LenzDavid R Gandara

Published in: Cancer chemotherapy and pharmacology (2018)

While the combination of cixutumumab and sorafenib had a toxicity profile similar to that of sorafenib monotherapy, it manifested limited clinical efficacy in unselected patients with HCC.

Keyphrases

combination therapy
clinical trial
study protocol
phase iii
phase ii